Healthcare - Biotechnology - NASDAQ - US
$ 11.14
-3.88 %
$ 499 M
Market Cap
-20.63
P/E
BALANCE SHEET
128 M
ASSETS
26.9 M
LIABILITIES
101 M
EQUITY
BALANCE SHEET DECOMPOSITION
Balance Sheet Decomposition
Y-mAbs Therapeutics, Inc.
| Current Assets | 111 M |
| Cash & Short-Term Investments | 78.6 M |
| Receivables | 22.5 M |
| Other Current Assets | 10 M |
| Non-Current Assets | 16.8 M |
| Long-Term Investments | 0 |
| PP&E | 1.64 M |
| Other Non-Current Assets | 15.1 M |
| Current Liabilities | 20.1 M |
| Accounts Payable | 6.06 M |
| Short-Term Debt | 1.8 M |
| Other Current Liabilities | 12.3 M |
| Non-Current Liabilities | 6.76 M |
| Long-Term Debt | 517 K |
| Other Non-Current Liabilities | 6.24 M |
Balance Sheet
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | Dec-2016 | |
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Cash & Cash Equivalents | 78.6 | 105.8 | 181.6 | 114.6 | 207.1 | 147.8 | 90.5 | 16.9 |
| Short Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 22.5 | 12.5 | 7.7 | 0 | 0 | 0 | 0 | 0 |
| Inventory | 5.1 | 6.7 | 5.5 | (0.8) | 0 | 0 | 0 | 0 |
| Other Current Assets | 5.0 | 5.5 | 7.5 | 7.7 | 4.8 | 3.7 | 0.9 | 0.4 |
| Total Current Assets | 111.1 | 130.4 | 202.3 | 122.4 | 212.0 | 151.5 | 91.4 | 17.3 |
| PP&E | 1.6 | 2.3 | 5.7 | 6.4 | 4.0 | 0.2 | 0 | 0 |
| Intangible Assets | 2.6 | 3.0 | 1.7 | 0 | 0 | 0 | 0 | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Long Term Assets | 12.5 | 5.7 | 3.2 | 3.3 | 0.4 | 0.2 | 0.8 | 0 |
| Other Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | 127.9 | 141.5 | 212.8 | 132.0 | 216.4 | 151.9 | 92.1 | 17.3 |
| LIABILITIES | ||||||||
| Accounts Payable | 6.1 | 14.2 | 13.6 | 9.4 | 8.5 | 5.9 | 5.9 | 2.2 |
| Short Term Debt | 1.8 | 1.7 | 3.6 | 3.9 | 1.0 | 0 | 0 | 0 |
| Other Current Liabilities | 12.3 | 12.4 | 10.8 | 6.2 | 4.0 | 3.3 | 2.0 | 0.7 |
| Total Current Liabilities | 20.1 | 28.3 | 27.9 | 19.5 | 13.6 | 9.1 | 7.9 | 3.0 |
| Long Term Debt | 0.5 | 0.9 | 1.9 | 2.0 | 1.7 | 0 | 0 | 0 |
| Deferred Tax Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities | 6.2 | 3.1 | 3.0 | 4.7 | 2.2 | 2.3 | 2.0 | 2.2 |
| Total Liabilities | 26.9 | 32.2 | 32.7 | 26.2 | 17.5 | 11.4 | 10.0 | 5.2 |
| EQUITY | ||||||||
| Common Stock | 4 K | 4 K | 4 K | 4 K | 4 K | 3 K | 3 K | 2 K |
| Retained Earnings | (457.5) | (436.0) | (340.5) | (285.2) | (165.9) | (84.8) | (41.6) | (22.4) |
| Other Accumulative Comprehensive Income/Loss | 0.4 | 1.3 | 1.4 | (0.5) | 50 K | 7 K | (0.2) | 30 K |
| Total Equity | 101.0 | 109.2 | 180.1 | 105.8 | 198.9 | 140.5 | 82.2 | 12.1 |
| Total Liabilities and Equity | 127.9 | 141.5 | 212.8 | 132.0 | 216.4 | 151.9 | 92.1 | 17.3 |
| SHARES OUTSTANDING | ||||||||
| Common Shares Outstanding | 43.6 | 43.7 | 43.2 | 40.1 | 35.2 | 28.8 | 33.3 | 33.3 |